Consensus $4.83. Lowers FY26 revenue view to up 1%-4% from up 3%-6%.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics reports Q2 adjusted EPS $1.27, consensus $1.11
- Haemonetics (HAE) Q2 Earnings Cheat Sheet
- Haemonetics: Strategic Adjustments and Growth Potential Justify Buy Rating Despite Revenue Challenges
- Haemonetics price target lowered to $64 from $78 at Citi
- Haemonetics Poised for Recovery and Growth: Buy Rating Affirmed Amid Strategic Actions and Strong Segment Performance